IgM-gammopathy strongly favours immune treatable MMN and MADSAM over ALS

What is it about?

Investigated was whether the discovery of an IgM-gammopathy can serve as a useful biomarker in the distinction of ALS vs immune treatable mimics such as MMN and motor predominant MADSAM. In one of the largest cohorts described to date of MMN (65 cases) and MADSAM (78 cases) cases the presence of an IgM-gammopathy made it significantly more likely that patients would have these immune treatable disorders over ALS (412 cases) (Odds Ratio of 33). Approximately a quarter of all MMN and MADSAM patients were identified to have IgM-gammopathy and their treatment response did not seem altered by the presence of this monoclonal protein.

Featured Image